NCT06934252View on ClinicalTrials.gov

Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

May 2, 2025

Primary Completion Date

July 20, 2026

Study Completion Date

June 22, 2027

Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
DRUG

TRB-061

Single subcutaneous injection of TRB-061 at escalating doses

DRUG

TRB-061

Subcutaneous TRB-061 administered every 4 weeks for a total of 4 doses

DRUG

TRB-061

Subcutaneous TRB-061 administered every 4 weeks for 3 doses

DRUG

Placebo

Single and multiple Subcutaneous doses of placebo matching TRB-061 in patients.

Trial Locations (1)

5000

RECRUITING

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
lead

TRex Bio, Inc.

INDUSTRY